Endometrial cancer and patterns of use of oestrogen replacement therapy: a cohort study
- PMID: 2930713
- PMCID: PMC2247072
- DOI: 10.1038/bjc.1989.91
Endometrial cancer and patterns of use of oestrogen replacement therapy: a cohort study
Abstract
5,160 non-hysterectomised women aged 44-100 years completed a health survey questionnaire as part of a longitudinal study of a southern California retirement community begun in June 1981. As of 1 January 1987, 50 incident cancers of the endometrium had occurred among these women, who had contributed 23,786 years of follow-up. Women who had used oestrogen replacement therapy had a relative risk of endometrial cancer of 10 compared to women who had never used oestrogens (P less than 0.0001). Risk increased with increasing duration of use (chi 2 test for trend = 50.60, P less than 0.0001); women who had used oestrogens for 15 or more years had a relative risk of 20 (95% C.I. = 7.2, 54) compared to non-users. While current and recent users (i.e. those who had used oestrogen within one year of the initial survey) had the greatest risk (RR = 25, 95% C.I. = 9.2, 69), women who had last used oestrogens 15 or more years ago still had a significantly increased risk (RR = 5.8, 95% C.I. = 2.0, 17). No other variable studied had a major effect on risk, except smoking. Women who smoked at the time of menopause had a significantly reduced risk of disease (RR = 0.38, P = 0.005), which was essentially unchanged after adjustment for oestrogen use.
Similar articles
-
Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study.BMJ. 1989 Jan 21;298(6667):147-51. doi: 10.1136/bmj.298.6667.147. BMJ. 1989. PMID: 2538173 Free PMC article.
-
The dose-effect relationship between 'unopposed' oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk.Br J Cancer. 1988 Feb;57(2):205-12. doi: 10.1038/bjc.1988.44. Br J Cancer. 1988. PMID: 3358913 Free PMC article.
-
Endometrial cancer and hormone-replacement therapy in the Million Women Study.Lancet. 2005 Apr 30-May 6;365(9470):1543-51. doi: 10.1016/S0140-6736(05)66455-0. Lancet. 2005. PMID: 15866308
-
The risk of endometrial carcinoma from oestrogen therapy of the menopause.Acta Endocrinol Suppl (Copenh). 1980;233:29-35. Acta Endocrinol Suppl (Copenh). 1980. PMID: 6773285 Review.
-
Endometrial carcinoma risk factors, with special reference to the use of oestrogens.Acta Endocrinol Suppl (Copenh). 1980;233:37-43. Acta Endocrinol Suppl (Copenh). 1980. PMID: 6996404 Review.
Cited by
-
Risks, Benefits, and Treatment Modalities of Menopausal Hormone Therapy: Current Concepts.Front Endocrinol (Lausanne). 2021 Mar 26;12:564781. doi: 10.3389/fendo.2021.564781. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 33841322 Free PMC article. Review.
-
Menopausal hormone therapy and risk of endometrial cancer.J Steroid Biochem Mol Biol. 2014 Jul;142:83-9. doi: 10.1016/j.jsbmb.2013.05.001. Epub 2013 May 13. J Steroid Biochem Mol Biol. 2014. PMID: 23680641 Free PMC article.
-
Prolonged endometrial stimulation associated with oestradiol implants.BMJ. 1990 Feb 17;300(6722):436-8. doi: 10.1136/bmj.300.6722.436. BMJ. 1990. PMID: 2107895 Free PMC article.
-
Who Should Receive Hormone Replacement Therapy?J Thromb Thrombolysis. 1996;3(1):13-21. doi: 10.1007/BF00226405. J Thromb Thrombolysis. 1996. PMID: 10608035
-
Role of androgens, progestins and tibolone in the treatment of menopausal symptoms: a review of the clinical evidence.Clin Interv Aging. 2008;3(1):1-8. doi: 10.2147/cia.s1043. Clin Interv Aging. 2008. PMID: 18488873 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials